VERU Stock Analysis: Buy, Sell, or Hold?
VERU - Veru Inc.
$2.26
0.02 (0.89%)
▲
5d:
-0.88%
30d:
-26.14%
90d:
+0.0%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 11, 2026
6d
Get Alerted When VERU Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: VERU shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: VERU shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: VERU is currently trading at $2.26, which is considered slightly low relative to its 30-day fair value range of $2.22 to $2.89.
Technical Outlook: Technically, VERU is in a uptrend. Immediate support is located at $2.16, while resistance sits at $2.41.
Market Sentiment: VERU has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (23th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $24.50 (+984.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, VERU is in a uptrend. Immediate support is located at $2.16, while resistance sits at $2.41.
Market Sentiment: VERU has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (23th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $24.50 (+984.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$2.22 -
$2.89
Company Quality Score
54/100
(HOLD)
Options IV Signal
23th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 23th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 984.1% below Wall St target ($24.50)
Trading Range Analysis
30-Day Trading Range
$2.22 -
$2.89
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$0.83
(36.9%)
Support & Resistance Levels
Support Level
$2.16
Resistance Level
$2.41
Current Trend
Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.29
Wall Street Target
$24.50
(+984.1%)
Revenue Growth (YoY)
18.3%
Share & Embed Analysis
Last updated: August 04, 2026 1:09 AM ET
Data refreshes hourly during market hours. Next update: 2:09 AM
Data refreshes hourly during market hours. Next update: 2:09 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VERU showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$416 | 53 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$386 | 43 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$196 | 47 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$557 | 49 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 54 HOLD |
